Malaria vaccine live attenuated - Sanaria

Drug Profile

Malaria vaccine live attenuated - Sanaria

Alternative Names: Pf delta b9 delta Slarp; PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; PfSPZ-GA1; Pf∆b9∆Slarp; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ Vaccine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
  • Class Attenuated vaccines; Malaria vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in Mali (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention) in USA (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Falciparum-malaria(Prevention, In volunteers) in Tanzania (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top